Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pharmacokinetic evaluation of pemetrexed

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

INTRODUCTION: Dose-response curves for efficacy and tolerability are the important determinants for the choice of doses of acute migraine drugs. Areas covered: Dose-response curves for the efficacy of seven triptans (5-HT1B/1D receptor agonists), a 5-HT1F receptor agonist (lasmiditan) and four oral calcitonin-gene related peptide receptor antagonists (telcagepant, MK-3207, BI 44370 TA and BMS-927711) in placebo-controlled trials were reviewed. In addition, dose-response curves for adverse events (AEs) were reviewed. Expert opinion: For most triptans, the dose-response curve for efficacy is flat, whereas AEs often increase with increasing doses. The two other groups of drugs also have flat dose-response curves for efficacy. Overall, the triptans still have the most favorable efficacy-tolerability profile. Current acute antimigraine drugs do not fulfill the expectations of the patients, and thus, there are many unmet needs. Although upcoming drugs may not be superior to triptans, migraine patients will potentially benefit greatly from these, especially patients who are triptan non-responders and patients with cardiovascular disease.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Metabolism & Toxicology
Vol/bind11
Udgave nummer9
Sider (fra-til)1409-1418
ISSN1742-5255
DOI
StatusUdgivet - 22 jun. 2015

ID: 45515180